Analysts expect Agilent Technologies (NYSE:A) to report $1.21 billion in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Agilent Technologies’ earnings, with the highest sales estimate coming in at $1.21 billion and the lowest estimate coming in at $1.20 billion. Agilent Technologies posted sales of $1.10 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 10%. The company is expected to report its next quarterly earnings results on Monday, May 28th.
On average, analysts expect that Agilent Technologies will report full year sales of $1.21 billion for the current year, with estimates ranging from $4.89 billion to $5.03 billion. For the next financial year, analysts anticipate that the company will report sales of $5.22 billion per share, with estimates ranging from $5.15 billion to $5.40 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Agilent Technologies.
Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $0.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.58 by $0.08. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.16 billion. Agilent Technologies had a net margin of 4.25% and a return on equity of 17.70%. During the same period in the prior year, the firm earned $0.53 earnings per share.
Several equities research analysts have commented on A shares. Barclays reaffirmed a “buy” rating and set a $74.00 price objective on shares of Agilent Technologies in a report on Monday, January 8th. Evercore ISI started coverage on shares of Agilent Technologies in a report on Wednesday, January 3rd. They set an “outperform” rating and a $75.00 price objective on the stock. Zacks Investment Research raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 price objective on the stock in a report on Tuesday, March 27th. Robert W. Baird reaffirmed a “buy” rating and set a $76.00 price objective on shares of Agilent Technologies in a report on Thursday, January 18th. Finally, ValuEngine downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $72.48.
NYSE A traded up $1.54 during trading on Monday, hitting $65.19. 2,606,557 shares of the company’s stock traded hands, compared to its average volume of 2,521,908. The company has a market cap of $20,525.60, a PE ratio of 27.62, a price-to-earnings-growth ratio of 2.19 and a beta of 1.31. Agilent Technologies has a 12-month low of $52.31 and a 12-month high of $75.00. The company has a quick ratio of 2.78, a current ratio of 3.23 and a debt-to-equity ratio of 0.40.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 25th. Stockholders of record on Tuesday, April 3rd will be given a dividend of $0.149 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Monday, April 2nd. Agilent Technologies’s dividend payout ratio is presently 25.42%.
In related news, Director Heidi Fields sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 27th. The shares were sold at an average price of $68.09, for a total value of $340,450.00. Following the transaction, the director now directly owns 57,563 shares in the company, valued at $3,919,464.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Patrick Kaltenbach sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, March 29th. The stock was sold at an average price of $67.28, for a total transaction of $269,120.00. Following the completion of the transaction, the insider now owns 72,547 shares in the company, valued at $4,880,962.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,400 shares of company stock worth $4,809,327.
Several hedge funds have recently bought and sold shares of the stock. Xact Kapitalforvaltning AB increased its position in shares of Agilent Technologies by 15.5% in the fourth quarter. Xact Kapitalforvaltning AB now owns 30,195 shares of the medical research company’s stock worth $2,022,000 after purchasing an additional 4,063 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in Agilent Technologies by 51.6% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 12,550 shares of the medical research company’s stock worth $816,000 after buying an additional 4,273 shares in the last quarter. Compagnie Lombard Odier SCmA purchased a new stake in Agilent Technologies in the fourth quarter worth approximately $126,000. OLD Mutual Customised Solutions Proprietary Ltd. boosted its stake in Agilent Technologies by 50.0% in the fourth quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 18,600 shares of the medical research company’s stock worth $1,246,000 after buying an additional 6,200 shares in the last quarter. Finally, Sterling Capital Management LLC boosted its stake in Agilent Technologies by 10.8% in the fourth quarter. Sterling Capital Management LLC now owns 100,870 shares of the medical research company’s stock worth $6,755,000 after buying an additional 9,822 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/09/agilent-technologies-a-expected-to-announce-quarterly-sales-of-1-21-billion.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Get a free copy of the Zacks research report on Agilent Technologies (A)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.